MoonLake Immunotherapeutics financials
$11.45−0.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$61.7M | -$70.0M | -$65.2M | -$71.4M | -$60.7M | -$47.5M | -$49.6M | -$43.1M | -$30.6M | -$19.8M | -$15.0M | -$13.0M |
| Net income | -$61.8M | -$69.7M | -$60.0M | -$70.7M | -$55.2M | -$39.9M | -$44.1M | -$36.1M | -$24.3M | -$13.7M | -$7.4M | -$9.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.84 | $-0.98 | $-0.88 | $-1.10 | $-0.87 | $-0.63 | $-0.70 | $-0.56 | $-0.39 | $-0.22 | $-0.12 | $-0.18 |
| EBITDA | -$60.8M | -$69.2M | -$64.5M | -$70.7M | -$60.0M | -$47.1M | -$49.2M | -$42.8M | -$30.2M | -$19.5M | -$15.0M | -$13.0M |
| Operating cash flow | -$55.6M | -$66.3M | -$58.8M | -$44.5M | -$54.5M | -$38.1M | -$48.5M | -$25.3M | -$27.9M | -$14.9M | -$12.3M | -$9.3M |
| Free cash flow | -$55.6M | -$66.3M | -$58.8M | -$44.5M | -$54.5M | -$38.2M | -$48.6M | -$25.4M | -$27.9M | -$15.2M | -$12.6M | -$9.3M |
| Diluted shares | 73.9M | 71.3M | 68.0M | 63.4M | 63.3M | 63.2M | 63.1M | 62.9M | 62.9M | 62.6M | 60.2M | 53.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $477.9M | $298.5M | $334.5M | $350.7M | $306.7M | $271.6M |
| Short-term investments | $59.1M | $59.4M | $59.5M | $29.7M | $118.4M | $208.6M |
| Total debt | $99.5M | $99.0M | $74.1M | $73.7M | $73.4M | $73.0M |
| Total assets | $573.9M | $400.4M | $424.4M | $414.3M | $460.1M | $511.3M |
| Total liabilities | $145.8M | $146.3M | $120.0M | $123.1M | $102.2M | $98.7M |
| Shareholders' equity | $428.2M | $254.0M | $304.5M | $291.2M | $357.9M | $412.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology